Authors say these estimates are similar to estimates in hospitalized patients
FRIDAY, Aug. 20, 2021 (HealthDay News) — The majority of individuals who experience mild or moderate COVID-19 infection have persistent symptoms more than 30 days after diagnosis, according to a study published online Aug. 4 in PLOS ONE.
Melanie L. Bell, Ph.D., from the University of Arizona in Tucson, and colleagues estimated the prevalence of postacute sequelae of COVID-19 (PASC) — defined as experiencing at least one symptom ≥30 days — and the prevalence of individual symptoms among 303 nonhospitalized individuals with a positive lab-confirmed COVID-19 test and mild or moderate disease with follow-up for a median 61 days.
The researchers found that the prevalence of PASC at 30 days postinfection was 68.7 percent. The median number of symptoms was three, with the most commonly reported symptoms including fatigue (37.5 percent), shortness of breath (37.5 percent), brain fog (30.8 percent), and stress/anxiety (30.8 percent). Among a subset of 157 participants with follow-up ≥60 days, PASC prevalence was 77.1 percent.
“This is a real wake-up call for anyone who has not been vaccinated,” Bell said in a statement. “If you get COVID, the chances that you’ll experience long-term symptoms are surprisingly high.”
ESMO: Combination Treatment Improves Survival in Muscle-Invasive Bladder Cancer
Broad Genomic Sequencing Improves Survival in First-Line Setting in Advanced NSCLC
1975 to 2017 Saw Increases in Survival for Children With Cancer
Chemo May Accelerate Biological Aging in Breast Cancer Survivors
Low Diagnostic Yield Seen for Postmastectomy Imaging in Patients With DCIS
Morphea Linked to Higher Risk for Cancer
PFOA and PFOS Linked to Increased Risk for ER-Negative Breast Cancer
Response to Autologous HSCT Durable for Patients With Systemic Sclerosis